Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sangamo Therapeutics stock

Learn how to easily invest in Sangamo Therapeutics stock.

Sangamo Therapeutics Inc is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Sangamo Therapeutics employs 431 staff and has a trailing 12-month revenue of around $114.2 million.

How to buy shares in Sangamo Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SGMO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Sangamo Therapeutics stock price (NASDAQ: SGMO)

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics shares at a glance

Information last updated 2022-10-02.
Latest market close$4.78
52-week range$3.12 - $11.49
50-day moving average $5.29
200-day moving average $5.32
Wall St. target price$14.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.21

Buy Sangamo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sangamo Therapeutics price performance over time

Historical closes compared with the close of $4.78 from 2022-10-03

1 week (2022-09-27) -4.59%
1 month (2022-09-02) -13.56%
3 months (2022-07-01) 11.68%
6 months (2022-03-31) N/A
1 year (2021-10-04) -45.74%
2 years (2020-10-02) -48.21%
3 years (2019-10-04) 8.53
5 years (2017-10-04) 17

Sangamo Therapeutics financials

Revenue TTM $114.2 million
Gross profit TTM $-120,118,000
Return on assets TTM -15.43%
Return on equity TTM -45.13%
Profit margin -150.96%
Book value $2.08
Market capitalisation $767.1 million

TTM: trailing 12 months

Sangamo Therapeutics share dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.

Sangamo Therapeutics share price volatility

Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $3.12 up to $11.49. A popular way to gauge a stock's volatility is its "beta".

SGMO.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.3168. This would suggest that Sangamo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc. ; Kite Pharma, Inc.

Frequently asked questions

What percentage of Sangamo Therapeutics is owned by insiders or institutions?
Currently 15.907% of Sangamo Therapeutics shares are held by insiders and 59.124% by institutions.
How many people work for Sangamo Therapeutics?
Latest data suggests 431 work at Sangamo Therapeutics.
When does the fiscal year end for Sangamo Therapeutics?
Sangamo Therapeutics's fiscal year ends in December.
Where is Sangamo Therapeutics based?
Sangamo Therapeutics's address is: , Brisbane, CA, United States, 94005
What is Sangamo Therapeutics's ISIN number?
Sangamo Therapeutics's international securities identification number is: US8006771062
What is Sangamo Therapeutics's CUSIP number?
Sangamo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 800677106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site